Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
1.1Glucose lowering with metformin
What ifWhat if the formulation delivers metformin hydrochloride for blood glucose control?
Claim language“one or more analgesic agents”
Micronized metformin hydrochloride disperses as solid particles during mixing with the molten lipid blend. After ingestion, digestion of the lipid matrix exposes the particles, and gastrointestinal fluid dissolves the drug.
1.2Wax ester solid matrix
What ifWhat if cetyl palmitate forms the solid matrix around the liquid lipids?
Claim language“one or more saturated C10-C22 triglycerides”
Cetyl palmitate melts during blending with the liquid lipids and crystallizes during cooling. The wax crystals form a network that immobilizes the liquid fraction, and drug release proceeds by diffusion and lipid digestion.
1.2Ethyl oleate liquid phase
What ifWhat if ethyl oleate supplies the liquid fraction of the lipid matrix?
Claim language“a mixture of unsaturated C14-C22 monoglycerides, unsaturated C14-C22 diglycerides, and unsaturated C14-C22 triglycerides”
Ethyl oleate dissolves a lipophilic active agent and blends with the molten saturated triglycerides. During cooling, the triglycerides crystallize and retain the ethyl oleate solution in the spaces between crystals.
1.3Polyether surfactant for dispersion
What ifWhat if a polyethylene oxide–polypropylene oxide block copolymer promotes lipid dispersion?
Claim language“one or more free C14-24 fatty acid surfactants”
Poloxamer 188 hydrates when the formulation contacts gastrointestinal fluid. Its polypropylene oxide block associates with the lipid surface, and its hydrated polyethylene oxide blocks limit droplet coalescence.
1.4Aqueous suspension of lipid particles
What ifWhat if the drug-loaded lipid matrix is supplied as solid particles in a water-based suspension?
Claim language“an anhydrous formulation”
Spray congealing converts the molten drug–lipid blend into solid particles. The particles disperse in an aqueous xanthan gum vehicle, which slows their separation during storage.
Section 2 · machine-generated
Variations
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
Other field of use
Single dose paste for veterinary use
An anthelmintic is dispersed in a carrier containing saturated triglycerides, unsaturated mono-, di-, and triglycerides, and a free long-chain fatty acid. The carrier is warmed for mixing and metered into single-dose oral syringes while it flows. On cooling, the saturated triglycerides form a semisolid paste that the plunger dispenses directly into the animal's mouth.
Component substitution
Wax ester as the solid structurant
Cetyl palmitate, a wax ester, replaces the saturated triglyceride fraction as the solid structurant. The wax ester is melted into the unsaturated glycerolipid blend, and the active agent and free long-chain fatty acid are mixed into the liquid carrier. The blend is cast into unit doses, where the wax ester crystallizes during cooling and sets the matrix.
Parameter or scale variation
Two sizes of solid lipid beads
An anhydrous blend of saturated triglycerides, unsaturated glycerolipids, free long-chain fatty acid, and a dispersed active agent feeds two heated droplet-forming nozzles. The nozzles produce separate bead lots with nominal diameters of 0.8 mm and 2.0 mm by depositing droplets onto a cooled belt. The solid beads are sieved by size and filled into capsules by mass, with the smaller beads providing more surface area per gram.
Combination with existing systems
Lipid fill in enteric capsules
A positive-displacement pump meters the anhydrous drug and lipid mixture into preformed two-piece enteric capsule shells. The fill contains saturated triglycerides, an unsaturated glycerolipid blend, and a free long-chain fatty acid. The fill sets inside the shells, and the closed capsules are band-sealed at the cap-body seam. The shell opens at intestinal pH and exposes the lipid matrix to digestive fluid.
Lipid matrix in a layered tablet
A continuous process cools the anhydrous drug, glycerolipid, and fatty acid blend into a solid sheet and mills the sheet into granules. A bilayer tablet press meters the lipid granules into the first layer and a blend of mannitol and crospovidone into the second layer. In digestive fluid, the second layer breaks up and exposes the compressed lipid layer for contact with the fluid.
Automated or data-driven variant
Sensor control of lipid fill mass
A jacketed hopper holds an anhydrous suspension of the active agent in the glycerolipid and fatty acid carrier. A temperature sensor feeds a controller that adjusts jacket heating, and a low-speed agitator keeps the suspended solids distributed during filling. An inline checkweigher measures each filled unit, and the controller adjusts the dosing pump stroke from the rolling mean of recent fill weights.
Specific version of a part
Ibuprofen in a lipid matrix
Ibuprofen supplies the analgesic activity. The drug dissolves in the warm liquid lipid fraction before blending with the molten hard fat.
Trilaurin and oleoyl glycerides
Trilaurin accounts for 55% of the total formulation by weight. Glyceryl monooleate, glyceryl dioleate, and glyceryl trioleate each contribute 10%, bringing the total glycerolipid content to 85% by weight.
Free oleic acid blend
Free oleic acid accounts for 20% of the total formulation by weight and mixes into the molten glycerolipids. During intestinal dispersion, oleic acid partitions into colloidal structures containing bile salts and lipid digestion products.
Anhydrous hot melt fill
Dry active powder and dry lipid excipients mix under dry nitrogen above the melting point of the hard fat. The blend transfers into unit-dose containers while fluid and solidifies on cooling.
Section 3 · quoted from USPTO records
Other work
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
1.1a) one or more pharmaceutically active agents, the one or more pharmaceutically active agents being selected from the group consisting of one or more analgesic agents, one or more antiallergic agents, one or more antiandrogen agents, one or more antiangiogenic agents, one or more anticonvulsant agents, one or more antidyssomnia agents, one or more antiemetic agents, one or more anthelmintic agents, one or more antifibrotic agents, one or more antihyperlipidemic agents, one or more anti-inflammatory agents, one or more antineoplastic agents, one or more antiparasitic agents, one or more antipsychotic agents, one or more dermatological agents, one or more hematological agents, one or more immunologic agents, one or more immunomodulating agents, one or more immunostimulant agents, one or more immunosuppressive agents, or any combination thereof;
The subject invention provides a pharmaceutical formulation in the form of an oily solution for injection to a subject comprising a contraceptively and/or therapeutically effective amount of a long-acting progestogen and a contraceptively and/or therapeutically effective amount of a long-acting androgen dissolved in a pharmaceutically acceptable oily medium wherein the injection is administered by the subject itself with a needle-less device, a mini-needle device or a pre-fil
A · US 2006/0094698 A1 · abstract
1.2b) about 45% to about 95% by weight of the pharmaceutical composition of one or more glycerolipids, the one or more glycerolipids being one or more saturated C10-C22 triglycerides and a mixture of unsaturated C14-C22 monoglycerides, unsaturated C14-C22 diglycerides, and unsaturated C14-C22 triglycerides; and
The fat-and-oil composition of the present invention contains 1,2-saturated-3-unsaturated glycerides (SSU) (hereinafter referred to as SSU type triglycerides) in an amount of 15% by weight or more and 1,3-saturated-2-unsaturated glycerides (SUS) (hereinafter referred to as SUS type triglycerides) in an amount of less than 50% by weight in the fats and oils.
B · US 2009/0022875 A1 · ¶ 14
1.3c) about 1.0% to about 8.0% by weight of the pharmaceutical composition of one or more free C14-24 fatty acid surfactants, about 15% to about 40% by weight of the pharmaceutical composition of one or more free C14-24 fatty acids, or both the one or more free C14-24 fatty acid surfactants and the one or more free C14-24 fatty acids;
Further, the good inhibitory function of the migration of water can be imparted by addition of at least one ingredient selected from mono-diglycerides, sorbitan tristearate and acetylated sucrose fatty acid esters to the above-mentioned fat-and-oil composition. In this case, preferably, such an ingredient is added in an amount of 15% by weight or less to the fat-and-oil composition.
B · US 2009/0022875 A1 · ¶ 18
1.4wherein the pharmaceutical composition is an anhydrous formulation, and
1.5wherein the pharmaceutical composition is not an emulsion.
The subject invention provides a pharmaceutical formulation in the form of an oily solution for injection to a subject comprising a contraceptively and/or therapeutically effective amount of a long-acting progestogen and a contraceptively and/or therapeutically effective amount of a long-acting androgen dissolved in a pharmaceutically acceptable oily medium wherein the injection is administered by the subject itself with a needle-less device, a mini-needle device or a pre-fil
A · US 2006/0094698 A1 · abstract
An empty cell means only that no passage was reproduced there.
Statements in these documents
However, no effective and efficient methods of male contraception are as of yet available.
A · US 2006/0094698 A1 · ¶ 3
Administration of progestagen results in a dose dependent suppression of pituitary gonadotrophins and consequently, a decrease in testosterone levels and a reversible inhibition of spermatogenesis.
A · US 2006/0094698 A1 · ¶ 5
The present invention relates to a fat-and-oil composition for inhibiting the migration of water in a food product and a food product using the same.
B · US 2009/0022875 A1 · ¶ 1
However, since water migrates among different materials with the lapse of time after production, the mouthfeel, for example, the crispy and crunchy feel of a low-water-content material is lost, which causes a problem of deterioration of a product value.
B · US 2009/0022875 A1 · ¶ 2
Cite aspatent.fyi, US 2026/0355320 A1, claim 1, first published 2026-11-19T10:32:39-05:00, https://patent.fyi/US20260355320/, SHA-256 e7627fa924f9cbb85a504ae4a947dcf5bd082a04c43d6c4c136f4bb26fb77441